New coccidiosis vaccine establishes early immunity
Jan. 26, 2011
by Meat&Poultry Staff
RALEIGH, N.C. – Pfizer Poultry Health is introducing to US poultry producers a new option to optimize protection against coccidiosis. Inovocox EM1 is specially formulated to fight coccidiosis – the intestinal parasitic disease with an annual estimated global economic impact exceeding $3 billion.
The new formulation accompanies the vaccine Inovocox – launched in early 2009 – as the first and only coccidiosis vaccines specifically licensed and designed for in ovo administration, the company relayed.
Both vaccines contain Eimeria acervulina and E. tenella. But unlike its relative, Inovocox EM1 contains only one strain of E. maxima, which means there is a reduced risk of disturbing the enterocytes of the midgut and a lower incidence of necrotic enteritis. Inovocox EM1 is the optimal choice for environmental or management conditions that make it challenging for coccidiosis vaccines to be successful.
“Pfizer Poultry Health created two distinct formulations with breeder operations in mind,” said Dr. Jon Schaeffer, director of veterinary operations at Pfizer. “Because no two operations are the same, veterinarians can help producers select the best vaccine for the individual conditions and specific coccidiosis challenge that each unit faces.
“In conditions that favor necrotic enteritis, such as wet litter, extended brooding, high pH soil, poor ventilation, etc., Inovocox EM1 is the solution of choice,” he added.
The new vaccine is a good partner for the Embrex Inovoject System, which can deliver a precise and uniform dose of either Inovocox or Inovocox EM1 in ovo to 18- or 19-day-old embryonated chicken eggs, the company said.
“In the case of coccidiosis, in ovo administration enables precise coccidiosis control across the entire flock at the earliest possible point in a chicken’s life -while it is still in the egg,” Schaeffer said. “Coccidiosis is difficult to control once it takes hold in a flock, making early prevention a priority for poultry producers.
“Acquiring early immunity from Inovocox gives other coccidiosis management tools a head start in maintaining flock health,” he added.
Inovocox EM1and Inovocox are the only coccidiosis vaccines approved by the USDA to be co-administered in ovo with Marek’s and bursal disease vaccines, he continued. This versatility provides producers with unique options for immunizing flocks while enhancing feed conversion.
Feed conversion is frequently used to measure the effectiveness of a coccidiosis control program in broilers, which is why achieving early, strong and long-lasting immunity with Inovocox vaccines is the key to high-performing flocks.
Pfizer Poultry Health, a business unit of Pfizer Animal Health, is a leading provider of innovative, high-performance poultry health solutions to the global poultry industry.